MG
HZNP

Michael Gelband’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Michael Gelband’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,446
Closed -$1.44M – 2185
2023
Q3 		$1.44M Sell
12,446
-18,153
-59% -$1.95M 0.01% 815
2023
Q2 		$3.15M Buy
+30,599
New +$3.23M 0.03% 622
2022
Q4 		– Sell
-119,485
Closed -$7.39M – 2323
2022
Q3 		$7.39M Buy
119,485
+8,664
+8% +$605K 0.1% 284
2022
Q2 		$8.84M Buy
110,821
+56,558
+104% +$5.36M 0.11% 219
2022
Q1 		$5.71M Sell
54,263
-7,552
-12% -$736K 0.07% 336
2021
Q4 		$6.66M Buy
61,815
+9,904
+19% +$1.08M 0.07% 333
2021
Q3 		$5.69M Buy
+51,911
New +$5.39M 0.08% 348
2021
Q1 		– Sell
-8,713
Closed -$637K – 2858
2020
Q4 		$637K Sell
8,713
-335,855
-97% -$25M 0.01% 1102
2020
Q3 		$26.8M Buy
344,568
+291,253
+546% +$20M 0.53% 19
2020
Q2 		$2.96M Buy
+53,315
New +$2.28M 0.08% 295
2019
Q3 		– Sell
-61,610
Closed -$1.48M – 1790
2019
Q2 		$1.48M Buy
+61,610
New +$1.56M 0.06% 196

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Michael Gelband's HZNP Position: Q4 2023 in Review

Michael Gelband sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 12,446 shares — an estimated $1.44M sold.

Michael Gelband first reported a position in HZNP in Q2 2019 and held it in 11 quarters. The position peaked at $26.8M in Q3 2020. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Michael Gelband reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Michael Gelband sold 12,446 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.44M.
  • Michael Gelband first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2019 and held it in 11 quarters.
  • Michael Gelband's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $26.8M in Q3 2020.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on ExodusPoint Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.